Aliases & Classifications for Meniere Disease

MalaCards integrated aliases for Meniere Disease:

Name: Meniere Disease 57 12 53 25 37 44 40 73
Meniere's Disease 12 53 25 43 15
Ménière's Disease 53 25 6
Otogenic Vertigo 12 25
Primary Endolymphatic Hydrops 25
Meniere's Syndrome 25
M�ni�re's Disease 76
Ménière's Vertigo 25
Auditory Vertigo 25
Menieres Disease 55
Mnire's Vertigo 12
Ménière Disease 25
Vertigo, Aural 73
Aural Vertigo 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
incomplete penetrance
onset usually between 30 and 50 years of age
prevalence of 0.5 to 1 in 1,000


HPO:

32
meniere disease:
Onset and clinical course incomplete penetrance
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases


Summaries for Meniere Disease

MedlinePlus : 43 Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss. Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have "drop attacks" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders

MalaCards based summary : Meniere Disease, also known as meniere's disease, is related to active cochleovestibular meniere's disease and active vestibular meniere's disease, and has symptoms including vertigo, tinnitus and snoring. An important gene associated with Meniere Disease is FAM136A (Family With Sequence Similarity 136 Member A), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Histamine and Betahistine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and bone, and related phenotypes are hearing impairment and vertigo

Disease Ontology : 12 A vestibular disease characterized by vertigo, low-pitched tinnitus and hearing loss.

Genetics Home Reference : 25 Ménière disease is a disorder of the inner ear that affects balance and hearing. This condition is characterized by sudden episodes of extreme dizziness (vertigo), a roaring sound in the ears (tinnitus), a feeling of pressure or fullness in the ears, and fluctuations in hearing. Episodes are often associated with nausea and vomiting, and they can severely disrupt activities of daily living.

NIH Rare Diseases : 53 Ménière's disease is an abnormality of the inner ear. Signs and symptoms may include disabling vertigo or severe dizziness lasting from minutes to hours; tinnitus or a roaring sound in the ears; fluctuating hearing loss; and the sensation of pressure or pain in the affected ear. A small percentage of people have drop attacks. The disorder usually affects only one ear, but some people develop symptoms in both ears many years after their initial diagnosis. Although the exact cause of Ménière's disease is unknown, the symptoms are thought to be associated with a change in fluid volume within a portion of the inner ear known as the labyrinth. Treatment may include medications or surgery depending on the severity of the condition.

OMIM : 57 Meniere disease is a chronic illness characterized by intermittent episodes of vertigo lasting from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural pressure (Sajjadi and Paparella, 2008). (156000)

Wikipedia : 76 Ménière''s disease (MD) is a disorder of the inner ear that is characterized by episodes of feeling like... more...

Related Diseases for Meniere Disease

Diseases related to Meniere Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 active cochleovestibular meniere's disease 11.1
2 active vestibular meniere's disease 11.1
3 active cochlear meniere's disease 11.1
4 kanzaki disease 11.1
5 inappropriate adh syndrome 10.2 AQP4 AQP2
6 motion sickness 10.2 FAM136A AQP1
7 central pontine myelinolysis 10.2 AQP4 AQP1
8 superior semicircular canal dehiscence 10.2 SEMA3D COCH
9 subependymoma 10.2 AQP4 AQP1
10 idiopathic edema 10.2 AQP2 AQP1
11 peripheral vertigo 10.1 FAM136A COCH AQP2
12 vestibular disease 10.1 FAM136A COCH AQP2
13 deafness, autosomal dominant 15 10.1 FAM136A DTNA
14 neuromyelitis optica 10.1 AQP4 AQP1
15 aplasia of lacrimal and salivary glands 10.1 MIP AQP5
16 deafness, autosomal dominant 28 10.1 FAM136A DTNA
17 intracranial hypertension 10.1 AQP4 AQP1
18 hydrops, lactic acidosis, and sideroblastic anemia 10.1 MIP AQP4
19 impaired renal function disease 10.1 AQP3 AQP2 AQP1
20 bullous keratopathy 10.1 MIP AQP3
21 dysferlinopathy 10.1 MIP AQP4 AQP1
22 polyhydramnios 10.0 AQP3 AQP1
23 brain edema 10.0 MIP AQP4 AQP1
24 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.0 AQP3 AQP2
25 deafness, autosomal dominant 9 10.0 SLC44A2 FAM136A COCH
26 vertigo, benign recurrent 9.9
27 benign paroxysmal positional nystagmus 9.9
28 mastocytosis 9.9
29 oligohydramnios 9.9 AQP3 AQP1
30 pityriasis rubra pilaris 9.9
31 alopecia 9.9
32 venous insufficiency 9.9
33 hypoparathyroidism 9.9
34 acoustic neuroma 9.9
35 neuritis 9.9
36 pathologic nystagmus 9.9
37 alopecia areata 9.9
38 hydrarthrosis 9.8 MIP AQP7 AQP3 AQP1
39 diabetes insipidus, nephrogenic, autosomal 9.8 MIP AQP4 AQP3 AQP2 AQP1

Comorbidity relations with Meniere Disease via Phenotypic Disease Network (PDN):


Active Vestibular Meniere's Disease Anxiety
Esophagitis Hypertension, Essential
Hypothyroidism Ischemic Heart Disease
Labyrinthitis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Meniere Disease:



Diseases related to Meniere Disease

Symptoms & Phenotypes for Meniere Disease

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Ears:
tinnitus
vertigo, episodic
hearing impairment, sensorineural, fluctuating
aural fullness


Clinical features from OMIM:

156000

Human phenotypes related to Meniere Disease:

32
# Description HPO Frequency HPO Source Accession
1 hearing impairment 32 HP:0000365
2 vertigo 32 HP:0002321
3 tinnitus 32 HP:0000360

UMLS symptoms related to Meniere Disease:


vertigo, tinnitus, snoring, coughing, sore throat, vertigo/dizziness, equilibration disorder

MGI Mouse Phenotypes related to Meniere Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.1 AQP1 AQP3 AQP4 AQP5 COCH SLC44A2

Drugs & Therapeutics for Meniere Disease

Drugs for Meniere Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
2
Betahistine Approved, Investigational Phase 4,Phase 2 5638-76-6 2366
3
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
4
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
6
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
8
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
14
Histamine Phosphate Phase 4,Phase 2 51-74-1 65513
15 Vasodilator Agents Phase 4,Phase 2
16 Sildenafil Citrate Phase 4 171599-83-0
17 Phosphodiesterase Inhibitors Phase 4
18 Citrate Phase 4
19 Phosphodiesterase 5 Inhibitors Phase 4
20 Trace Elements Phase 4
21 Vitamin B9 Phase 4
22 Vitamins Phase 4
23 Tocotrienols Phase 4
24 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Autonomic Agents Phase 4,Phase 2,Phase 3
27 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Vitamin B3 Phase 4
29 Antioxidants Phase 4,Phase 2,Phase 1
30 Folate Phase 4
31 Antiemetics Phase 4,Phase 2,Phase 3
32 Nicotinic Acids Phase 4
33 Antimetabolites Phase 4,Phase 3
34 Lipid Regulating Agents Phase 4
35 Hypolipidemic Agents Phase 4
36 Tocopherols Phase 4
37 Micronutrients Phase 4
38 Vitamin B Complex Phase 4
39 Pharmaceutical Solutions Phase 4,Phase 2
40 BB 1101 Phase 4,Phase 3,Phase 2
41 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
42
protease inhibitors Phase 4
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
44 Dexamethasone 21-phosphate Phase 4
45 HIV Protease Inhibitors Phase 4
46 glucocorticoids Phase 4,Phase 2,Phase 3
47 Hormone Antagonists Phase 4,Phase 2,Phase 3
48 Hormones Phase 4,Phase 2,Phase 3
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
50
Acyclovir Approved Phase 2, Phase 3 59277-89-3 2022

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Recruiting NCT02530931 Phase 4 Gadolinium
2 Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
3 Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 Sildenafil For Meniere's Disease Completed NCT00145483 Phase 4 Sildenafil
5 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
6 Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Completed NCT02718846 Phase 4 Meniace;Isobide
7 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Recruiting NCT02529475 Phase 4 Gadoteric acid
8 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4 Dexamethasone Phosphate
9 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
10 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Terminated NCT02717442 Phase 3 OTO-104;Placebo
11 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Completed NCT02612337 Phase 3 OTO-104;Placebo
12 Famvir for Treatment of Hearing in Unilateral Meniere's Disease Terminated NCT01526408 Phase 3 Famciclovir;Placebo
13 Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Recruiting NCT03664674 Phase 3 OTO-104;Placebo
14 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
15 Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease Completed NCT00802529 Phase 2, Phase 3 Methylprednisolone;Gentamicin
16 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02768662 Phase 3 OTO-104
17 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02706730 Phase 3 OTO-104
18 Study of Lamotrigine to Treat Ménière's Disease Completed NCT02158585 Phase 3 Lamotrigine;Placebo
19 Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury Recruiting NCT03339505 Phase 3
20 Latanoprost for the Treatment of Menière's Disease Unknown status NCT01973114 Phase 2 Latanoprost
21 SPI-1005 for the Treatment of Patients With Meniere's Disease Recruiting NCT03325790 Phase 2 200mg SPI-1005 BID;400mg SPI-1005 BID
22 OTO-104 for the Treatment of Meniere's Disease Completed NCT01412177 Phase 2 OTO-104;Placebo
23 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
24 Open Label Study of OTO-104 in Subjects With Meniere's Disease Terminated NCT02740387 Phase 2 OTO-104
25 A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom Completed NCT02265393 Phase 2 OTO-104;Placebo
26 Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain Completed NCT00709202 Phase 2 Betahistine;Placebo Oral Tablet
27 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
28 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
29 OTO-104 for Meniere's Disease Completed NCT01084525 Phase 1 OTO-104 (steroid) 3 mg;Placebo;OTO-104 (steroid) 12 mg
30 Vasopressin and V2 Receptor in Meniere's Disease Completed NCT00599560 Not Applicable
31 A Study of a Mastoid Device in Subjects With Ménière's Disease Not yet recruiting NCT03520322 Not Applicable
32 Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis? Withdrawn NCT02371798 Not Applicable Gadopentetate dimeglumine
33 Effects of Endolymphatic Sac Drainage With Steroids for Meniere’s Disease Completed NCT00500474 Not Applicable
34 Stress Management Therapy for Meniere's Disease Recruiting NCT01099046 Not Applicable
35 CI Following VS Removal or Labyrinthectomy Recruiting NCT03795675 Not Applicable
36 Comparison of 3 Methods to Diagnose Endolymphatic Hydrops in Meniere's Disease Recruiting NCT03215420 Not Applicable
37 Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent Completed NCT02080312 Not Applicable Magnevist (gadopentetate dimeglumine)
38 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099 Not Applicable
39 Consequence of Unilateral Vestibular Loss on Visual Abilities Recruiting NCT03581331 Not Applicable
40 Herbal Medication (Gongjin-dan) for Chronic Dizziness Not yet recruiting NCT03219515 Not Applicable Gongjin-Dan;Placebo
41 Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI Recruiting NCT03593577
42 Preoperative Carbohydrate Loading in Patients Undergoing Day-case Cholecystectomy Completed NCT03757208 Not Applicable
43 Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice Completed NCT01759251
44 Transcranial Vibrating System for Improving Vestibular Physical Therapy Recruiting NCT03795168 Not Applicable
45 Healthful Diets and Risk of Hearing Loss Completed NCT03351023

Search NIH Clinical Center for Meniere Disease

Cochrane evidence based reviews: meniere disease

Genetic Tests for Meniere Disease

Anatomical Context for Meniere Disease

MalaCards organs/tissues related to Meniere Disease:

41
Testes, Brain, Bone, Salivary Gland, Eye, T Cells

Publications for Meniere Disease

Articles related to Meniere Disease:

(show top 50) (show all 430)
# Title Authors Year
1
Imaging of Ménière Disease. ( 30466641 )
2019
2
Proinflammatory cytokines and response to molds in mononuclear cells of patients with Meniere disease. ( 29654306 )
2018
3
Serum sickness disease in a patient with alopecia areata and Meniere' disease after PRP procedure. ( 30511475 )
2018
4
Sequential Imaging in Patient With Suspected Menière's Disease Identifies Endolymphatic Sac Tumor. ( 30124615 )
2018
5
Anatomical Variations in Patients with Ménière Disease: A Tomography Study. ( 29983760 )
2018
6
Intratympanic Therapies in Ménière Disease: Evaluation of Outcomes and Early Vertigo Control. ( 30284276 )
2018
7
MR Imaging in Menière Disease: Is the Contact between the Vestibular Endolymphatic Space and the Oval Window a Reliable Biomarker? ( 30337432 )
2018
8
Direction-Changing and Direction-Fixed Positional Nystagmus in Patients With Vestibular Neuritis and Meniere Disease. ( 30509014 )
2018
9
Association of Ménière disease with human leukocyte antigen in Taiwanese population. ( 30540889 )
2018
10
In vivo imaging of saccular hydrops in humans reflects sensorineural hearing loss rather than Meniere's disease symptoms. ( 29564597 )
2018
11
Vestibular syncope: A disorder associated with drop attack in Ménière's disease. ( 28478076 )
2018
12
Evaluating Quality of Life in Patients With Meniere's Disease Treated as Migraine. ( 30198300 )
2018
13
Simultaneous Presentation of Definite Vestibular Migraine and Definite Ménière's Disease: Overlapping Syndrome of Two Diseases. ( 30250448 )
2018
14
Newly Diagnosed Meniere's Disease: Clinical Course With Initiation of Noninvasive Treatment Including an Accounting of Vestibular Migraine. ( 29546771 )
2018
15
Patient, disease, and outcome characteristics of benign paroxysmal positional vertigo with and without Meniere's disease. ( 30016894 )
2018
16
Benign paroxysmal positional vertigo associated with Meniere's disease. ( 30149485 )
2018
17
Comorbid Symptoms Occurring During Acute Low-Tone Hearing Loss (AHLH) as Potential Predictors of Menière's Disease. ( 30420828 )
2018
18
MRI in otology: applications in cholesteatoma and Ménière's disease. ( 28969854 )
2018
19
Association of Meniere's disease and retinal vascular calibre: a prospective observational study in China. ( 30282681 )
2018
20
Impact of Ménière's Disease on Significant Others' Health and Lives. ( 29309024 )
2018
21
The Progressive Nature of Menière's Disease: Stress Projections and Lesion Analysis. ( 29315186 )
2018
22
Relationship Between the Extent of Endolymphatic Hydrops and the Severity and Fluctuation of Audiovestibular Symptoms in Patients With Menière's Disease and MRI Evidence of Hydrops. ( 29315188 )
2018
23
International consensus (ICON) on treatment of Ménière's disease. ( 29338942 )
2018
24
Comparison of enhancement of the vestibular perilymph between gadoterate meglumine and gadobutrol at 3-Tesla in Meniere's disease. ( 29398574 )
2018
25
Treatment of vestibular disorders with weak asymmetric base-in prisms: An hypothesis with a focus on Ménière's disease. ( 29400688 )
2018
26
Instrumental head impulse test changes after intratympanic gentamicin for unilateral definite Ménière's disease: A systematic review and meta-analysis. ( 29402608 )
2018
27
Ménière's Disease Pathophysiology: Endolymphatic Sac Immunohistochemical Study of Aquaporin-2, V2R Vasopressin Receptor, NKCC2, and TRPV4. ( 29436285 )
2018
28
The Follow-Up Role of the Vestibular Evoked Myogenic Potential Test in Meniere's Disease. ( 29436794 )
2018
29
Pediatric Meniere's disease. ( 29447806 )
2018
30
Structural Analysis of Tensor Tympani Muscle, Tympanic Diaphragm, Epitympanum, and Protympanum in Menière's Disease: a Human Temporal Bone Study. ( 29498964 )
2018
31
On the classification of hydropic ear disease (Menière's disease). ( 29500497 )
2018
32
Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. ( 29532287 )
2018
33
Thomsen J et al. - The non-specific effect of endolymphatic sac surgery in treatment of Meniere's disease: A prospective, randomized controlled study comparing "classic" endolymphatic sac surgery with the insertion of a ventilating tube in tympanic membrane. Acta Oto-Laryngol 1998: 118: 769-773. ( 29532729 )
2018
34
In Vivo Morphometric Analysis of Human Cranial Nerves Using Magnetic Resonance Imaging in Menière's Disease Ears and Normal Hearing Ears. ( 29553505 )
2018
35
Comment on "Mastoid and Inner Ear Measurements in Patients With MeniÈre's Disease". ( 29561379 )
2018
36
Comment on "Mastoid and Inner Ear Measurements in Patients With MeniÈre's Disease". ( 29561380 )
2018
37
Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere's disease: Preliminary study. ( 29573626 )
2018
38
Intratympanic Gentamicin for Intractable Ménière's Disease - A Review and Analysis of Audiovestibular Impact. ( 29619111 )
2018
39
Clinical Subtyping of Ménière's Disease. ( 29688822 )
2018
40
Relationship Between Audio-Vestibular Functional Tests and Inner Ear MRI in Meniere's Disease. ( 29698363 )
2018
41
Alcohol consumption in Menière's disease patients. ( 29733259 )
2018
42
Endolymphatic Sac Decompression With Intra-Sac Dexamethasone Injection in Menière's Disease. ( 29738389 )
2018
43
Comparison of VEMPs, VHIT and caloric test outcomes after vestibular neurectomy in Menière's disease. ( 29747962 )
2018
44
High-Frequency Horizontal Semicircular Canal Function in Certain Menière's Disease. ( 29762197 )
2018
45
Vestibulo-Cochlear Function After Cochlear Implantation in Patients With Meniere's Disease. ( 29764776 )
2018
46
Impact of Tumarkin attacks on complaints and work ability in Ménière's disease. ( 29843293 )
2018
47
Vitamin D supplementation may improve symptoms in Meniere's disease. ( 29857909 )
2018
48
Low Concentration Intra-Tympanic Gentamicin Treatment for Menière's Disease: A Long-Term Follow Up. ( 29995010 )
2018
49
Endolymphatic duct blockage for refractory Ménière's disease: assessment of intraoperative CSF leak on short-term surgical outcomes. ( 30016910 )
2018
50
Correlation between auditory-vestibular functions and estrogen levels in postmenopausal patients with Meniere's disease. ( 30030864 )
2018

Variations for Meniere Disease

ClinVar genetic disease variations for Meniere Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FAM136A NM_032822.2(FAM136A): c.226C> T (p.Gln76Ter) single nucleotide variant Pathogenic rs690016537 GRCh37 Chromosome 2, 70527974: 70527974
2 FAM136A NM_032822.2(FAM136A): c.226C> T (p.Gln76Ter) single nucleotide variant Pathogenic rs690016537 GRCh38 Chromosome 2, 70300842: 70300842
3 DTNA NM_001198938.1(DTNA): c.1963G> T (p.Val655Phe) single nucleotide variant Likely pathogenic rs533568822 GRCh38 Chromosome 18, 34882130: 34882130
4 DTNA NM_001198938.1(DTNA): c.1963G> T (p.Val655Phe) single nucleotide variant Likely pathogenic rs533568822 GRCh37 Chromosome 18, 32462094: 32462094

Expression for Meniere Disease

Search GEO for disease gene expression data for Meniere Disease.

Pathways for Meniere Disease

Pathways related to Meniere Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
2
Show member pathways
12.69 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
3
Show member pathways
11.58 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
4 11.08 AQP2 AQP3 AQP4
5 10.92 AQP3 AQP5

GO Terms for Meniere Disease

Cellular components related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 AQP1 AQP5 AQP7 MIP SEMA3D TLR10
2 apical plasma membrane GO:0016324 9.46 AQP1 AQP2 AQP5 MIP
3 basal plasma membrane GO:0009925 9.4 AQP1 AQP5
4 plasma membrane GO:0005886 9.36 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
5 basolateral plasma membrane GO:0016323 9.26 AQP1 AQP2 AQP3 AQP4
6 integral component of membrane GO:0016021 10.07 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
7 membrane GO:0016020 10.03 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7

Biological processes related to Meniere Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.76 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
2 excretion GO:0007588 9.62 AQP2 AQP3 AQP5 AQP7
3 odontogenesis GO:0042476 9.61 AQP1 AQP3 AQP5
4 renal water homeostasis GO:0003091 9.56 AQP1 AQP2 AQP3 AQP4
5 cellular response to copper ion GO:0071280 9.51 AQP1 AQP2
6 multicellular organismal water homeostasis GO:0050891 9.49 AQP1 AQP4
7 pancreatic juice secretion GO:0030157 9.48 AQP1 AQP5
8 carbon dioxide transport GO:0015670 9.46 AQP1 AQP5
9 cellular response to mercury ion GO:0071288 9.4 AQP1 AQP2
10 renal water transport GO:0003097 9.37 AQP1 AQP2
11 glycerol transport GO:0015793 9.26 AQP1 AQP2 AQP3 AQP7
12 water transport GO:0006833 9.17 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7

Molecular functions related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.5 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7
2 water transmembrane transporter activity GO:0005372 9.33 AQP1 AQP2 AQP4
3 glycerol channel activity GO:0015254 9.32 AQP3 AQP7
4 glycerol transmembrane transporter activity GO:0015168 9.26 AQP1 AQP2
5 water channel activity GO:0015250 9.17 AQP1 AQP2 AQP3 AQP4 AQP5 AQP7

Sources for Meniere Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....